Paola Secchiero

List of Publications by Year
in descending order

277 papers	11,378 citations	34105 52 h-index	40979 93 g-index
284 all docs	284 docs citations	284 times ranked	13802 citing authors

#	Article	IF	Citations
1	Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood, 2004, 104, 2418-2424.	1.4	422
2	Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Medicine, 1997, 3, 1394-1397.	30.7	411
3	Detection of Human Herpesvirus 6 in Plasma of Children with Primary Infection and Immunosuppressed Patients by Polymerase Chain Reaction. Journal of Infectious Diseases, 1995, 171, 273-280.	4.0	295
4	Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7634-7639.	7.1	295
5	COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. International Journal of Molecular Sciences, 2020, 21, 3474.	4.1	290
6	TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways. Circulation, 2003, 107, 2250-2256.	1.6	283
7	CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3872-3876.	7.1	229
8	MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. Journal of Hematology and Oncology, 2017, 10, 133.	17.0	213
9	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 2010, 116, 945-952.	1.4	200
10	Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood, 2006, 107, 4122-4129.	1.4	156
11	Recent Advances in the Therapeutic Perspectives of Nutlin-3. Current Pharmaceutical Design, 2011, 17, 569-577.	1.9	150
12	Systemic Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein Eâ€"Null Diabetic Mice. Circulation, 2006, 114, 1522-1530.	1.6	147
13	An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction. American Journal of Pathology, 2006, 169, 2236-2244.	3.8	129
14	TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood, 2000, 95, 3716-24.	1.4	129
15	Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. PLoS ONE, 2010, 5, e11140.	2.5	128
16	Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3. Circulation Research, 2007, 100, 61-69.	4.5	124
17	TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cellular and Molecular Life Sciences, 2004, 61, 1965-1974.	5.4	123
18	Human Herpesvirus 6: A Survey of Presence and Variant Distribution in Normal Peripheral Lymphocytes and Lymphoproliferative Disorders. Journal of Infectious Diseases, 1994, 170, 211-215.	4.0	121

#	Article	IF	Citations
19	Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood, 2007, 110, 536-543.	1.4	121
20	The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine and Growth Factor Reviews, 2006, 17, 245-257.	7.2	120
21	Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand (TRAIL) Sequentially Upregulates Nitric Oxide and Prostanoid Production in Primary Human Endothelial Cells. Circulation Research, 2003, 92, 732-740.	4.5	119
22	TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood, 2004, 103, 517-522.	1.4	110
23	MiR-34a/c-Dependent PDGFR-Î±/Î² Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS ONE, 2013, 8, e67581.	2.5	103
24	TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood, 2004, 104, 2044-2050.	1.4	99
25	TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood, 2005, 105, 3413-3419.	1.4	98
26	Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factorâ€"related apoptosis-inducing ligand (TRAIL)â€"mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood, 2001, 97, 2596-2603.	1.4	93
27	Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis, 2011, 215, 452-458.	0.8	90
28	Evidence for a Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Anemia of Myelodysplastic Syndromes. American Journal of Pathology, 2005, 166, 557-563.	3.8	89
29	MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8650-8655.	7.1	86
30	The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies. Current Pharmaceutical Design, 2008, 14, 2100-2110.	1.9	85
31	Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. Journal of Immunology, 1999, 162, 2427-31.	0.8	85
32	Tumor necrosis factorâ€"related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood, 2002, 100, 2421-2429.	1.4	83
33	Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood, 2009, 113, 4300-4308.	1.4	83
34	Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction. PLoS ONE, 2009, 4, e4442.	2.5	82
35	Quantitative PCR for human herpesviruses 6 and 7. Journal of Clinical Microbiology, 1995, 33, 2124-2130.	3.9	80
36	Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. Journal of Virology, 1997, 71, 4571-4580.	3.4	80

#	Article	IF	Citations
37	HIV-1 Tat-mediated Inhibition of the Tyrosine Hydroxylase Gene Expression in Dopaminergic Neuronal Cells. Journal of Biological Chemistry, 2000, 275, 4159-4165.	3.4	77
38	Latent BK virus infection and Kaposi's sarcoma pathogenesis. , 1996, 66, 717-722.		72
39	Role of full-length osteoprotegerin in tumor cell biology. Cellular and Molecular Life Sciences, 2009, 66, 841-851.	5.4	70
40	T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities. Frontiers in Immunology, 2018, 9, 1390.	4.8	70
41	Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factorâ€“related apoptosis-inducing ligandâ€“mediated cytotoxicity on hematologic malignancies. Blood, 2001, 98, 2220-2228.	1.4	69
42	Synergistic Cytotoxic Activity of Recombinant TRAIL Plus the Non-Genotoxic Activator of the p53 Pathway Nutlin-3 in Acute Myeloid Leukemia Cells. Current Drug Metabolism, 2007, 8, 395-403.	1.2	69
43	miR-34a Induces the Downregulation of BothE2F1andB-MybOncogenes in Leukemic Cells. Clinical Cancer Research, 2011, 17, 2712-2724.	7.0	69
44	A set of NF-ÎºBâ€“regulated microRNAs induces acquired TRAIL resistance in Lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3355-64.	7.1	68
45	Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. Journal of Neurochemistry, 2004, 86, 126-135.	3.9	67
46	Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Current Opinion in Hematology, 2008, 15, 42-48.	2.5	66
47	Human herpesvirus 6 (variant A) in Kaposi's sarcoma. Lancet, The, 1993, 341, 1288-1289.	13.7	63
48	TRAIL inhibits osteoclastic differentiation by counteracting RANKLâ€dependent p27^{Kip1} accumulation in preâ€osteoclast precursors. Journal of Cellular Physiology, 2008, 214, 117-125.	4.1	61
49	An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis, 2010, 210, 274-277.	0.8	61
50	Treatment With Recombinant Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligand Alleviates the Severity of Streptozotocin-Induced Diabetes. Diabetes, 2010, 59, 1261-1265.	0.6	58
51	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Promotes Migration of Human Bone Marrow Multipotent Stromal Cells. Stem Cells, 2008, 26, 2955-2963.	3.2	56
52	Evidence for a Proangiogenic Activity of TNF-Related Apoptosis-Inducing Ligand. Neoplasia, 2004, 6, 364-373.	5.3	55
53	Biological and Molecular Characteristics of Human Herpesvirus 7: In Vitro Growth Optimization and Development of a Syncytia Inhibition Test. Virology, 1994, 202, 506-512.	2.4	54
54	Actively targeted nanocarriers for drug delivery to cancer cells. Expert Opinion on Drug Delivery, 2019, 16, 481-496.	5.0	52

#	Article	IF	Citations
55	Presence and physical state of HPV DNA in prostate and urinary-tract tissues. International Journal of Cancer, 1992, 52, 359-365.	5.1	51
56	Osteoprotegerin promotes vascular fibrosis via a TGF-Î²1 autocrine loop. Atherosclerosis, 2011, 218, 61-68.	0.8	51
57	HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts. Scientific Reports, 2018, 8, 17665.	3.3	50
58	Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway. Clinical Cancer Research, 2011, 17, 762-770.	7.0	48
59	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Molecular and Cellular Endocrinology, 2014, 394, 13-20.	3.2	48
60	Increased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis. Scientific Reports, 2019, 9, 10870.	3.3	48
61	Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis. Nanoscale, 2013, 5, 7897.	5.6	47
62	Identification of human telomeric repeat motifs at the genome termini of human herpesvirus 7: structural analysis and heterogeneity. Journal of Virology, 1995, 69, 8041-8045.	3.4	47
63	Human Immunodeficiency Virus Type 1 Nef Protein Sensitizes CD4+ T Lymphoid Cells to Apoptosis via Functional Upregulation of the CD95/CD95 Ligand Pathway. Blood, 1999, 93, 1000-1010.	1.4	45
64	The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica, 2012, 97, 1722-1730.	3.5	44
65	TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clinical Science, 2012, 123, 547-555.	4.3	44
66	Applications of nanoparticles in cancer medicine and beyond: optical and multimodalin vivoimaging, tissue targeting and drug delivery. Expert Opinion on Drug Delivery, 2015, 12, 1837-1849.	5.0	44
67	Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. Cancers, 2020, 12, 2126.	3.7	44
68	TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies. Current Pharmaceutical Design, 2004, 10, 3673-3681.	1.9	43
69	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. American Journal of Pathology, 2005, 167, 1599-1607.	3.8	43
70	The 85-kilodalton phosphoprotein (pp85) of human herpesvirus 7 is encoded by open reading frame U14 and localizes to a tegument substructure in virion particles. Journal of Virology, 1997, 71, 5758-5763.	3.4	42
71	Endothelial Cells Obtained from Patients Affected by Chronic Venous Disease Exhibit a Pro-Inflammatory Phenotype. PLoS ONE, 2012, 7, e39543.	2.5	42
72	The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts. Neoplasia, 2007, 9, 853-861.	5.3	41

#	Article	IF	Citations
73	Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases. PLoS ONE, 2018, 13, e0193867.	2.5	40
74	Infection of CD34+ hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). Blood, 2000, 96, 126-131.	1.4	39
75	Cell-Based Therapies for Diabetic Complications. Experimental Diabetes Research, 2012, 2012, 1-10.	3.8	39
76	Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis). Circulation Journal, 2009, 73, 1973-1982.	1.6	38
77	Human Herpesvirus 7 induces CD4(+) T-cell death by two distinct mechanisms: necrotic lysis in productively infected cells and apoptosis in uninfected or nonproductively infected cells. Blood, 1997, 90, 4502-12.	1.4	38
78	Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Blood, 1999, 93, 1000-10.	1.4	38
79	HIVâ€1 Tat protein downâ€regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3â€kinase/AKT/cyclic nucleoside phosphodiesterase pathway. FASEB Journal, 2001, 15, 483-491.	0.5	37
80	Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells. Journal of Immunology, 1999, 163, 3169-75.	0.8	37
81	Stromal derived factor-1 alpha (SDF-1 alpha) induces CD4+ T cell apoptosis via the functional up-regulation of the Fas (CD95)/Fas ligand (CD95L) pathway. Journal of Leukocyte Biology, 2001, 69, 263-70.	3.3	37
82	IFN-Î±2b Reduces IL-2 Production and IL-2 Receptor Function in Primary CD4+T Cells. Journal of Immunology, 2000, 164, 2296-2302.	0.8	36
83	C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1â€“Dependent Pathway. Clinical Cancer Research, 2013, 19, 1949-1959.	7.0	36
84	Clinical perspectives of TRAIL: insights into central nervous system disorders. Cellular and Molecular Life Sciences, 2016, 73, 2017-2027.	5.4	36
85	Human herpesvirus 6 and Epstein-Barr virus in Hodgkin's disease: a controlled study by polymerase chain reaction and in situ hybridization. American Journal of Pathology, 1996, 149, 1501-10.	3.8	36
86	Interference between human herpesvirus 7 and HIV-1 in mononuclear phagocytes. Journal of Immunology, 1996, 156, 2004-8.	0.8	36
87	Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. Journal of Cellular Physiology, 2006, 206, 647-654.	4.1	35
88	TRAIL Modulates the Immune System and Protects against the Development of Diabetes. Journal of Immunology Research, 2015, 2015, 1-12.	2.2	35
89	Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Molecular and Cellular Endocrinology, 2011, 331, 136-142.	3.2	34
90	Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity. International Journal of Biochemistry and Cell Biology, 2016, 81, 364-374.	2.8	34

#	Article	IF	Citations
91	Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology, 2006, 207, 158-164.	4.1	33
92	TRAIL and osteoprotegerin: a role in endothelial physiopathology?. Frontiers in Bioscience - Landmark, 2008, 13, 135.	3.0	33
93	NK-active cytokines IL-2, IL-12, and IL-15 selectively modulate specific protein kinase C (PKC) isoforms in primary human NK cells. The Anatomical Record, 2002, 266, 87-92.	1.8	32
94	Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factorâ€“related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4+ T cells. Blood, 2001, 98, 2474-2481.	1.4	31
95	State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 207-217.	1.6	31
96	TRAIL shows potential cardioprotective activity. Investigational New Drugs, 2012, 30, 1257-1260.	2.6	31
97	Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood, 2008, 111, 1287-1294.	1.4	30
98	Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis, 2010, 211, 333-336.	0.8	30
99	Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. Human Reproduction, 2012, 27, 2941-2947.	0.9	30
100	Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts. Clinical Cancer Research, 2013, 19, 3871-3880.	7.0	30
101	TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?. Clinical Science, 2019, 133, 1145-1166.	4.3	30
102	Accumulation of catalytically active PKC-Î¶ into the nucleus of HL-60 cell line plays a key role in the induction of granulocytic differentiation mediated by all-transretinoic acid. British Journal of Haematology, 1998, 100, 541-549.	2.5	29
103	Human Herpesvirus 7 Infection Induces Profound Cell Cycle Perturbations Coupled to Disregulation of cdc2 and Cyclin B and Polyploidization of CD4+ T Cells. Blood, 1998, 92, 1685-1696.	1.4	29
104	The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology, 2008, 48, 293-298.	1.9	29
105	In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome. PLoS ONE, 2013, 8, e56377.	2.5	29
106	Progressive and Persistent Downregulation of Surface CXCR4 in CD4+ T Cells Infected With Human Herpesvirus 7. Blood, 1998, 92, 4521-4528.	1.4	28
107	Human herpesvirus type 7 in Hodgkin's disease. British Journal of Haematology, 1998, 101, 492-499.	2.5	27
108	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-Î± promote the NF-ÎºB-dependent maturation of normal and leukemic myeloid cells. Journal of Leukocyte Biology, 2003, 74, 223-232.	3.3	27

#	Article	IF	Citations
109	MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53^{wildâ€type} CLL with a poor cytotoxic response to Nutlinâ€3. British Journal of Haematology, 2010, 150, 237-239.	2.5	27
110	Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology, 2005, 205, 246-252.	4.1	26
111	Contextâ€dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress. BioFactors, 2017, 43, 475-485.	5.4	26
112	CCR4+ Skin-Tropic Phenotype as a Feature of Central Memory CD8+ T Cells in Healthy Subjects and Psoriasis Patients. Frontiers in Immunology, 2020, 11, 529.	4.8	26
113	Engagement of CD28 Modulates CXC Chemokine Receptor 4 Surface Expression in Both Resting and CD3-Stimulated CD4+ T Cells. Journal of Immunology, 2000, 164, 4018-4024.	0.8	25
114	Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14620-14625.	7.1	25
115	Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. Journal of Cellular Physiology, 2005, 204, 975-982.	4.1	25
116	The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. Acta Diabetologica, 2014, 51, 239-246.	2.5	25
117	Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. Oncotarget, 2016, 7, 18965-18977.	1.8	25
118	In Vitro Susceptibility of Macaca nemestrina to Human Herpesvirus 6: A Potential Animal Model of Coinfection with Primate Immunodeficiency Viruses. AIDS Research and Human Retroviruses, 1994, 10, 181-187.	1.1	24
119	Identification and Analysis of a Novel Heparin-Binding Glycoprotein Encoded by Human Herpesvirus 7. Journal of Virology, 2000, 74, 4530-4540.	3.4	24
120	Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. Clinical Nutrition, 2013, 32, 259-264.	5.0	24
121	Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous disease. Cytokine, 2013, 63, 92-96.	3.2	24
122	Modulation of Circulating Cytokine-Chemokine Profile in Patients Affected by Chronic Venous Insufficiency Undergoing Surgical Hemodynamic Correction. Journal of Immunology Research, 2014, 2014, 1-10.	2.2	24
123	Sex/Gender-Specific Imbalance in CVD: Could Physical Activity Help to Improve Clinical Outcome Targeting CVD Molecular Mechanisms in Women?. International Journal of Molecular Sciences, 2020, 21, 1477.	4.1	24
124	Differential effects of stromal derived factor-1? (SDF-1?) on early and late stages of human megakaryocytic development. The Anatomical Record, 2000, 260, 141-147.	1.8	23
125	The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research, 2010, 16, 1824-1833.	7.0	23
126	Multimodal near-infrared-emitting PluS Silica nanoparticles with fluorescent, photoacoustic, and photothermal capabilities. International Journal of Nanomedicine, 2016, Volume 11, 4865-4874.	6.7	23

#	Article	IF	Citations
127	Upregulation of the alternative splicing factor NOVA2 in colorectal cancer vasculature. OncoTargets and Therapy, 2018, Volume 11, 6049-6056.	2.0	23
128	Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis. Frontiers in Neurology, 2018, 9, 245.	2.4	23
129	MDM2 Antagonist Nutlin-3 Suppresses the Proliferation and Differentiation of Human Pre-Osteoclasts Through a p53-Dependent Pathway. Journal of Bone and Mineral Research, 2007, 22, 1621-1630.	2.8	22
130	Ultrastructure of internal jugular vein defective valves. Phlebology, 2015, 30, 644-647.	1.2	22
131	Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. Journal of Medicinal Chemistry, 2016, 59, 147-156.	6.4	22
132	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. Oncogene, 2017, 36, 6617-6626.	5.9	22
133	Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. Oncotarget, 2014, 5, 4347-4360.	1.8	22
134	Association of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Central Adiposity and Low-Density Lipoprotein Cholesterol. PLoS ONE, 2013, 8, e58225.	2.5	21
135	Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. Oncotarget, 2016, 7, 70623-70638.	1.8	21
136	The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. Acta Diabetologica, 2013, 50, 899-906.	2.5	20
137	Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells. Journal of Cellular Physiology, 2016, 231, 2700-2710.	4.1	20
138	SARS-CoV-2 nucleocapsid protein and ultrastructural modifications in small bowel of a 4-week-negative COVID-19 patient. Clinical Microbiology and Infection, 2021, 27, 936-937.	6.0	20
139	Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels. Journal of Immunology, 1997, 159, 3412-23.	0.8	20
140	TRAIL pathway components and their putative role in granulosa cell apoptosis in the human ovary. Differentiation, 2009, 77, 369-376.	1.9	19
141	TNF-Î± modulates the migratory response of mesenchymal stem cells to TRAIL. Cellular and Molecular Life Sciences, 2010, 67, 1307-1314.	5.4	19
142	The Î³-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. Oncotarget, 2017, 8, 59235-59245.	1.8	19
143	Characterization of Human Herpesvirus 6 Strains Isolated from Patients with Exanthem Subitum with or without Cutaneous Rash. Journal of Infectious Diseases, 1992, 166, 689-689.	4.0	18
144	Cloning, restriction endonuclease mapping and partial sequence analysis of the genome of human herpesvirus 7 strain JI. Journal of General Virology, 1996, 77, 1901-1912.	2.9	18

#	Article	IF	Citations
145	Inhibitory Effect of Natural Anti-Inflammatory Compounds on Cytokines Released by Chronic Venous Disease Patient-Derived Endothelial Cells. Mediators of Inflammation, 2013, 2013, 1-13.	3.0	18
146	Multiple dye-doped NIR-emitting silica nanoparticles for both flow cytometry and in vivo imaging. RSC Advances, 2014, 4, 18278-18285.	3.6	18
147	Oscillatory flow suppression improves inflammation in chronic venous disease. Journal of Surgical Research, 2016, 205, 238-245.	1.6	18
148	The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressIve MultiplE sclerosis patients (RAGTIME): study protocol for a randomized controlled trial. Trials, 2017, 18, 88.	1.6	18
149	Nutlin-3 Downregulates the Expression of the Oncogene TCL1 in Primary B Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research, 2011, 17, 5649-5655.	7.0	17
150	TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse. Clinical Science, 2018, 132, 69-83.	4.3	16
151	Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients. Frontiers in Pharmacology, 2020, 11, 1156.	3.5	16
152	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST. Frontiers in Oncology, 2020, 10, 504.	2.8	16
153	Purinergic Signaling and Inflammasome Activation in Psoriasis Pathogenesis. International Journal of Molecular Sciences, 2021, 22, 9449.	4.1	16
154	The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. Oncotarget, 2015, 6, 2385-2396.	1.8	16
155	Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model. PLoS ONE, 2014, 9, e115387.	2.5	15
156	Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. Journal of Leukocyte Biology, 2008, 83, 434-437.	3.3	14
157	Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. Journal of Clinical Virology, 2012, 55, 367-369.	3.1	14
158	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. Journal of Hematology and Oncology, 2013, 6, 83.	17.0	14
159	Inverse Correlation Between Circulating Levels of TNF-Related Apoptosis-Inducing Ligand and 17Î²-Estradiol. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E659-E664.	3.6	14
160	Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. PLoS ONE, 2018, 13, e0203716.	2.5	14
161	Development of Recombinant Diagnostic Reagents Based on pp85(U14) and p86(U11) Proteins To Detect the Human Immune Response to Human Herpesvirus 7 Infection. Journal of Clinical Microbiology, 1999, 37, 3980-3985.	3.9	14
162	Autoinflammatory Diseases and Cytokine Stormsâ€"Imbalances of Innate and Adaptative Immunity. International Journal of Molecular Sciences, 2021, 22, 11241.	4.1	14

#	Article	IF	Citations
163	TNF-related apoptosis-inducing ligand (TRAIL) up-regulates cyclooxygenase (COX)-1 activity and PGE(2) production in cells of the myeloid lineage. Journal of Leukocyte Biology, 2002, 72, 986-94.	3.3	14
164	Is vestibular papillomatosis associated with human papillomavirus?. Journal of Medical Virology, 1991, 35, 7-13.	5.0	13
165	Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. Experimental Hematology, 2004, 32, 925-934.	0.4	13
166	State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies. Current Medicinal Chemistry, 2012, 19, 4875-4884.	2.4	13
167	Plasma levels of soluble NCAM in multiple sclerosis. Journal of the Neurological Sciences, 2019, 396, 36-41.	0.6	13
168	The Italian law on body donation: A position paper of the Italian College of Anatomists. Annals of Anatomy, 2021, 238, 151761.	1.9	13
169	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. Current Drug Targets, 2012, 13, 1215-1221.	2.1	13
170	IFN-Î±2b Increases Interleukin-10 Expression in Primary Activated Human CD8+T Cells. Journal of Interferon and Cytokine Research, 2002, 22, 1167-1173.	1.2	12
171	Trail downâ€regulates the release of osteoprotegerin (OPG) by primary stromal cells. Journal of Cellular Physiology, 2011, 226, 2279-2286.	4.1	12
172	TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide. Cytokine, 2012, 60, 43-46.	3.2	12
173	Activation of the p53 pathway induces Î±â€smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. Journal of Cellular Physiology, 2012, 227, 1829-1837.	4.1	12
174	In VitroEndothelial Cell Proliferation Assay Reveals Distinct Levels of Proangiogenic Cytokines Characterizing Sera of Healthy Subjects and of Patients with Heart Failure. Mediators of Inflammation, 2014, 2014, 1-11.	3.0	12
175	Rehabilitation Improves Mitochondrial Energetics in Progressive Multiple Sclerosis: The Significant Role of Robot-Assisted Gait Training and of the Personalized Intensity. Diagnostics, 2020, 10, 834.	2.6	12
176	GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature. Diagnostics, 2021, 11, 604.	2.6	12
177	Nanoparticles Loaded with Nutlin-3 Display Cytotoxicity Towards p53^{wildtype} JVM-2 But Not Towards p53^{mutated} BJAB Leukemic Cells. Current Medicinal Chemistry, 2013, 20, 2712-2722.	2.4	12
178	TRAIL Activates a Caspase 9/7-Dependent Pathway in Caspase 8/10-Defective SK-N-SH Neuroblastoma Cells with Two Functional End Points: Induction of Apoptosis and PGE2 Release. Neoplasia, 2003, 5, 457-466.	5.3	11
179	Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. Journal of Cellular Physiology, 2007, 213, 229-236.	4.1	11
180	The Puzzling Role of TRAIL in Endothelial Cell Biology. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, e4; author reply e5-6.	2.4	11

#	Article	IF	Citations
181	Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table). Current Cancer Drug Targets, 2009, 9, 510-518.	1.6	11
182	Conjunctival sac fluid contains elevated levels of soluble TRAIL: Implications for the antiâ€tumoral surveillance of the anterior surface of the eye. Journal of Cellular Physiology, 2009, 218, 199-204.	4.1	11
183	Perifosine plus nutlinâ€3 combination shows a synergistic antiâ€leukaemic activity. British Journal of Haematology, 2010, 148, 957-961.	2.5	11
184	The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans. Clinical Nutrition, 2012, 31, 1018-1021.	5.0	11
185	GM-CSF Exhibits Anti-Inflammatory Activity on Endothelial Cells Derived from Chronic Venous Disease Patients. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	11
186	Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3. Molecular Carcinogenesis, 2014, 53, 498-504.	2.7	11
187	Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2016, 41, 273-280.	1.5	11
188	Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity. Frontiers in Physiology, 2018, 9, 1000.	2.8	11
189	Eosinophils and Purinergic Signaling in Health and Disease. Frontiers in Immunology, 2020, 11, 1339.	4.8	11
190	Anticancer Activity of Aqueous Extracts from Asparagus officinalis L. Byproduct on Breast Cancer Cells. Molecules, 2021, 26, 6369.	3.8	11
191	Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids. Molecules, 2022, 27, 471.	3.8	11
192	Dexamethasone counteracts the antiâ€osteoclastic, but not the antiâ€leukemic, activity of TNFâ€related apoptosis inducing ligand (TRAIL). Journal of Cellular Physiology, 2010, 222, 357-364.	4.1	10
193	Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus. Current Pharmaceutical Design, 2012, 18, 5759-5765.	1.9	10
194	Human Colostrum and Breast Milk Contain High Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL). Journal of Human Lactation, 2013, 29, 23-25.	1.6	10
195	Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells. Nutrition, 2013, 29, 332-337.	2.4	10
196	Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS). Genes, 2019, 10, 634.	2.4	10
197	Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFRA/SDH/RAS-P WT GIST. Scientific Reports, 2020, 10, 19829.	3.3	10
198	Colorectal Cancer Study with Nanostructured Sensors: Tumor Marker Screening of Patient Biopsies. Nanomaterials, 2020, 10, 606.	4.1	10

#	Article	IF	Citations
199	Stromal derived factor-1Î± induces apoptosis in activated primary CD4+ T cells. Aids, 2000, 14, 748-750.	2.2	10
200	Human Herpesvirus 7 Infection Induces Profound Cell Cycle Perturbations Coupled to Disregulation of cdc2 and Cyclin B and Polyploidization of CD4+ T Cells. Blood, 1998, 92, 1685-1696.	1.4	10
201	Infection of CD34+ hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). Blood, 2000, 96, 126-131.	1.4	10
202	Infection of CD34(+) hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). Blood, 2000, 96, 126-31.	1.4	10
203	Identification of Envelope Glycoproteins H and B Homologues of Human Herpesvirus 7. Intervirology, 1997, 40, 22-32.	2.8	9
204	Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies. Lupus, 2007, 16, 479-482.	1.6	9
205	Selection and Characterization of a Novel Agonistic Human Recombinant Anti-Trail-R2 Minibody with Antileukemic Activity. International Journal of Immunopathology and Pharmacology, 2009, 22, 73-83.	2.1	9
206	The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?. Rheumatology, 2010, 49, 1173-1176.	1.9	9
207	Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. Journal of Rheumatology, 2010, 37, 1461-1466.	2.0	9
208	The calendar of cytokines: Seasonal variation of circulating cytokines in chronic venous insufficiency. JRSM Cardiovascular Disease, 2017, 6, 204800401772927.	0.7	9
209	TRAIL treatment prevents renal morphological changes and TGF-Î²-induced mesenchymal transition associated with diabetic nephropathy. Clinical Science, 2020, 134, 2337-2352.	4.3	9
210	The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. Oncotarget, 2014, 5, 12635-12645.	1.8	9
211	Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. International Journal of Oncology, 2004, 25, 1599.	3.3	8
212	Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Modulates the Expression of Genes Involved in Apoptosis and Cell Cycle in Human Osteoclasts. Anatomical Record, 2007, 290, 838-845.	1.4	8
213	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. Current Drug Targets, 2012, 13, 1089-1095.	2.1	8
214	TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress. Mediators of Inflammation, 2018, 2018, 1-8.	3.0	8
215	The induction of megakaryocyte differentiation is accompanied by selective Ser133 phosphorylation of the transcription factor CREB in both HEL cell line and primary CD34+ cells. Blood, 1998, 92, 472-80.	1.4	8
216	The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. Leukemia, 2010, 24, 480-483.	7.2	7

#	Article	IF	Citations
217	The early determination of circulating TRAIL levels does not predict the development of pre-eclampsia. Placenta, 2012, 33, 135-136.	1.5	7
218	<scp>MCL</scp>1 downâ€regulation plays a critical role in mediating the higher antiâ€leukaemic activity of the multiâ€kinase inhibitor <scp>S</scp>orafenib with respect to <scp>D</scp>asatinib. British Journal of Haematology, 2012, 157, 510-514.	2.5	7
219	Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Show a Long-term Stability in the Breast Milk of Mothers of Preterm Infants. Journal of Human Lactation, 2013, 29, 350-353.	1.6	7
220	Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. Reproduction, 2014, 148, 191-198.	2.6	7
221	Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus. Acta Diabetologica, 2015, 52, 1003-1006.	2.5	7
222	Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors. Multiple Sclerosis and Related Disorders, 2020, 44, 102319.	2.0	7
223	Human herpesvirus 7 infection induces profound cell cycle perturbations coupled to disregulation of cdc2 and cyclin B and polyploidization of CD4(+) T cells. Blood, 1998, 92, 1685-96.	1.4	7
224	TRAIL, caspases and maturation of normal and leukemic myeloid precursors. Leukemia and Lymphoma, 2006, 47, 1459-1468.	1.3	6
225	Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin. Journal of Cellular and Molecular Medicine, 2008, 12, 1063-1065.	3.6	6
226	Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?. Annals of the Rheumatic Diseases, 2008, 67, 1196-1197.	0.9	6
227	Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2010, 69, 1733-1734.	0.9	6
228	Circulating TRAIL Shows a Significant Post-Partum Decline Associated to Stressful Conditions. PLoS ONE, 2011, 6, e27011.	2.5	6
229	Decreased levels of soluble TNF-related apoptosis-inducing ligand (TRAIL) in the conjunctival sac fluid of patients with diabetes affected by proliferative retinopathy. Diabetic Medicine, 2011, 28, 1277-1278.	2.3	6
230	Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Investigational New Drugs, 2012, 30, 1731-1735.	2.6	6
231	Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women. Mediators of Inflammation, 2017, 2017, 1-8.	3.0	6
232	Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells. Clinics, 2014, 69, 68-74.	1.5	6
233	Progressive and Persistent Downregulation of Surface CXCR4 in CD4+ T Cells Infected With Human Herpesvirus 7. Blood, 1998, 92, 4521-4528.	1.4	6
234	Enforced expression of humanbcl-2 in CD4+ T cells enhances human herpesvirus 7 replication and induction of cytopathic effects. European Journal of Immunology, 1998, 28, 1587-1596.	2.9	5

#	Article	IF	Citations
235	Letter by Secchiero and Zauli Regarding Article, â€œOsteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr ^(â^'/â^') Miceâ€•. Circulation, 2008, 118, e18; author reply e19.	1.6	5
236	Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opinion on Therapeutic Targets, 2011, 15, 931-942.	3.4	5
237	TRAIL, a New Weapon against Neointimal Hyperplasia. Cardiology, 2012, 123, 94-96.	1.4	5
238	JCV+ Patients with Inflammatory Bowel Disease show elevated plasma levels of MIG and SCF. Inflammatory Bowel Diseases, 2012, 18, 1194-1196.	1.9	5
239	Anti-leukemic activity of Dasatinib in both p53wild-type and p53mutated B malignant cells. Investigational New Drugs, 2012, 30, 417-422.	2.6	5
240	TNF-Related Apoptosis Inducing Ligand in Ocular Cancers and Ocular Diabetic Complications. BioMed Research International, 2015, 2015, 1-8.	1.9	5
241	MicroRNAs as New Players in the Genomic Galaxy and Disease Puzzles. Clinical and Translational Science, 2008, 1, 50-56.	3.1	4
242	Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Investigational New Drugs, 2012, 30, 803-807.	2.6	4
243	Role of vitamin D in the pathogenesis of atheromatosis. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 344-353.	2.6	4
244	MDM2 Non-Genotoxic Inhibitors as Innovative Therapeutic Approaches for the Treatment of Pediatric Malignancies. Current Medicinal Chemistry, 2013, 20, 2226-2236.	2.4	4
245	The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+Cells. Blood, 1998, 92, 472-480.	1.4	4
246	TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake. Cell Death and Disease, 2021, 12, 1089.	6.3	4
247	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. Frontiers in Oncology, 2021, 11, 778461.	2.8	4
248	The engagement of CD4 surface antigen in the HEL haemopoietic cell line upâ€•regulates the transforming growth factorâ€‰1 (TGFâ€‰1) promoter activity. British Journal of Haematology, 1997, 97, 571-578.	2.5	3
249	Role of TRAIL in osteoclastogenesis. Blood, 2008, 111, 5413-5413.	1.4	3
250	In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Investigational New Drugs, 2012, 30, 405-407.	2.6	3
251	Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. Investigational New Drugs, 2012, 30, 828-832.	2.6	3
252	Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumorsâ€”implications for therapeutic potential. Tumor Biology, 2016, 37, 11909-11916.	1.8	3

#	Article	IF	Citations
253	Novel Compliant Scaffold with Specific Design for Venous System: Results of a Porcine Model Study. BioMed Research International, 2018, 2018, 1-8.	1.9	3
254	Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients. Journal of Neuroimmunology, 2021, 352, 577473.	2.3	3
255	Progressive and persistent downregulation of surface CXCR4 in CD4(+) T cells infected with human herpesvirus 7. Blood, 1998, 92, 4521-8.	1.4	3
256	Reduced expression of cell cycleâ€associated genes in B lymphocytes purified from the peripheral blood of earlyâ€stage B chronic lymphocytic leukaemia patients. British Journal of Haematology, 2009, 145, 424-426.	2.5	2
257	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	12.6	2
258	Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1. Investigational New Drugs, 2013, 31, 780-786.	2.6	2
259	The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newborns. Cytokine, 2013, 64, 51-53.	3.2	2
260	Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy. Mediators of Inflammation, 2015, 2015, 1-7.	3.0	2
261	Expeditious Synthesis and Biological Characterization of Enantioâ€Enriched (â€)â€Nutlinâ€3. ChemistrySelect, 2017, 2, 8504-8508.	1.5	2
262	Association between thyroid hormones and TRAIL. Clinical Biochemistry, 2017, 50, 972-976.	1.9	2
263	Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors. Current Oncology, 2021, 28, 2439-2451.	2.2	2
264	Identification and Analysis of a Novel Heparin-Binding Glycoprotein Encoded by Human Herpesvirus 7. Journal of Virology, 2000, 74, 4530-4540.	3.4	2
265	Simultaneous determination of multiple cytokines reveals a pro-inflammatory and pro-angiogenic signature after major cardiothoracic surgery: Potential role of C-reactive protein. Cytokine, 2012, 60, 593-595.	3.2	1
266	The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Investigational New Drugs, 2012, 30, 810-818.	2.6	1
267	Association of Serum Tumor Necrosis Factor-Related Apoptosis Inducing Ligand with Body Fat Distribution as Assessed by Dual X-Rays Absorptiometry. Mediators of Inflammation, 2014, 2014, 1-6.	3.0	1
268	A novel endovenous scaffold for the treatment of chronic venous obstruction in a porcine model: Histological and ultrastructural assessment. Phlebology, 2019, 34, 336-346.	1.2	1
269	Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation. Biomolecules, 2021, 11, 1438.	4.0	1
270	AB0419â€…Frequency of disease flare and study of the cd4+cd25+highcd127low/- cell populations after discontinuation of anti-tnfî± therapy in patients with rheumatoid arthritisin persistent remission. , 2018, , .		1

#	Article	IF	Citations
271	The long and winding road may be getting shorter. Blood, 2005, 105, 4160-4160.	1.4	0
272	Potential involvement of TRAIL in Treg cellâ€“mediated osteoclast suppression: Comment on the article by Zaiss et al. Arthritis and Rheumatism, 2008, 58, 1887-1887.	6.7	0
273	TNFRSF11B (tumor necrosis factor receptor superfamily, member 11b). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
274	Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease. Experimental and Therapeutic Medicine, 2014, 8, 1906-1908.	1.8	0
275	Aberrant Expression of Trail in B Chronic Lymphocytic Leukemia (B-CLL) Cells.. Blood, 2005, 106, 4976-4976.	1.4	0
276	B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature.. Blood, 2009, 114, 4374-4374.	1.4	0
277	Merkel-Cell Polyomavirus Is Rarely Associated to B-Chronic Lymphocytic Leukemia and Occurs Late in the Natural History of the Disease. Blood, 2012, 120, 4578-4578.	1.4	0